Under the terms of the agreement, Natera will develop in vitro diagnostic products for oncology and pay Illumina milestone payments and royalties.
The GenomeWeb Index rose 4 percent in May, in line with the Nasdaq and the Nasdaq Biotech Index, and outperforming the Dow Jones Industrial Average.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
The company's first quarter revenues jumped due to an increase in NIPT and carrier screening testing volumes.
The results, presented at the AACR meeting, also included data from a subset of 50 patients who have so far been tested using Natera's multiplex PCR technology.
The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.
The company's quarterly revenue of $52.9 million blew away analyst estimates and its net loss of $.47 per share was better than analysts expected.
In the pilot study, Natera's technology detected ubiquitous and heterogeneous tumor mutation variants in early-stage non-small cell lung cancer blood samples.
The complaint alleges that Natera misled shareholders about its business prospects and did not disclose trends that it knew were having a negative impact.
The firm is using Natera's Constellation software platform, which provides cloud-based access to bioinformatics algorithms for clinical genomics applications.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.